Akebia Therapeutics (AKBA) Tops Q4 EPS by 14c

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of ($0.52), $0.14 better than the analyst estimate of ($0.66).

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
• Duluth Holdings Inc. (DLTH) Tops Q2 EPS by 49c
• DA Davidson Reiterates Buy Rating on Barrick Gold Corp. (GOLD)